Congress doubles funding for sickle cell disease research and treatment

What it does

This bill reauthorizes and expands a federal sickle cell disease research and treatment program. It broadens the program's scope to explicitly include prevention and treatment of complications (not just the disease itself), allows grants in addition to contracts, and nearly doubles annual funding from $4.46 million to $8.21 million for fiscal years 2025–2029. The bill benefits patients with sickle cell disease and related blood disorders by increasing research capacity and treatment options.

Why we flagged it

The bill is a straightforward reauthorization and expansion of an existing federal research and treatment program for a specific disease. It increases funding, broadens program scope, and adds administrative flexibility — all standard public-health legislative mechanics with no hidden riders or private carve-outs.

What the text implies

• Shift from 'prevention and treatment' to 'treatment and prevention of complications' may subtly de-emphasize primary prevention (e.g., genetic counseling, carrier screening) in favor of clinical management — though the bill does not explicitly restrict prevention work.
• Addition of grant authority alongside contracts may increase administrative burden on NIH/CDC but also enable smaller research institutions and community health centers to participate, potentially improving equity in research access.
• Reauthorization through 2029 provides multi-year funding certainty, allowing researchers to plan longer-term studies and reducing year-to-year uncertainty — a structural benefit to research continuity.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with sickle cell disease and related heritable blood disorders gain expanded research funding, broader treatment and complication-prevention services, and increased institutional capacity. The program reauthorization removes restrictive language and adds grant-making authority, enabling more diverse institutional participation and potentially faster innovation.

Who stands to gain

• National Institutes of Health (NIH) — receives expanded grant-making authority and increased appropr
• Centers for Disease Control and Prevention (CDC) — likely receives surveillance and prevention fundi
• Academic medical centers and research institutions — eligible for grants and contracts
• Community health centers and sickle cell disease treatment programs — potential grant recipients

Named in the bill

Public Health Service Act, Section 1106(b), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Sickle cell disease, Heritable blood disorders

Where it stands

6 cosponsors: 5 Democrats, 1 Republicans.

• Mar 3, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 3, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $180,000 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

John James, the sponsor, reported $224,000 in PAC receipts in the 2026 cycle.

• Fulcrum Therapeutics — $60,000 on 1 filing
• Sick Cells — $60,000 on 2 filings
• Leavitt Partners, LLC on Behalf of Sickle Cell Disease Partnership — $40,000 on 2 filings
• Terumo Bct, Inc. — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.